Key Points
-
Patients with IBD have a modestly increased risk of coronary heart disease and stroke
-
In patients with IBD, the magnitude of the increase in cardiovascular risk is higher in women than in men and in young adults (<40–50 years) than in older adults (>50–60 years)
-
Patients with IBD have evidence of premature vascular disease with structural, functional and biochemical changes indicative of subclinical atherosclerosis; IBD also promotes spontaneous platelet activation and aggregation, predisposing patients to atherothrombosis
-
Although conventional cardiovascular risk factors are not over-represented in patients with IBD, nonconventional chronic inflammation-based risk factors (IBD disease activity) are directly related to risk of cardiovascular events
-
Aggressive disease-modifying biologic therapy might favourably modify the risk of cardiovascular events in patients with IBD
-
Commonly used cardiovascular medications, such as statins, could improve IBD disease activity
Abstract
IBD is an established risk factor for venous thromboembolism. In the past few years, studies have suggested that patients with IBD might also be at an increased risk of coronary heart disease and stroke. The increased risk is thought to be similar to the level of risk seen in patients with other chronic systemic inflammatory diseases such as rheumatoid arthritis. The risk of developing these conditions is particularly increased in young adults with IBD, and more so in women than in men. Conventional cardiovascular risk factors are not over-represented in patients with IBD, so the increased risk could be attributable to inflammation-mediated atherosclerosis. Patients with IBD often have premature atherosclerosis and have biochemical and genetic markers similar to those seen in patients with atherosclerotic cardiovascular disease. The role of chronic inflammation in IBD-associated cardiovascular disease merits further evaluation. Particular attention should be given to the increased risk observed during periods of increased disease activity and potential modification of the risk by immunosuppressive and biologic therapies for IBD that can modify the disease activity. In addition, preclinical studies suggest that cardiovascular medications such as statins and angiotensin-converting enzyme inhibitors might also favourably modify IBD disease activity, which warrants further evaluation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Nguyen, G. C. et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology 146, 835–848 (2014).
Yuhara, H. et al. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 37, 953–962 (2013).
Grainge, M. J., West, J. & Card, T. R. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 375, 657–663 (2010).
Piazza, G. & Goldhaber, S. Z. Venous thromboembolism and atherothrombosis: an integrated approach. Circulation 121, 2146–2150 (2010).
Sorensen, H. T., Horvath-Puho, E., Pedersen, L., Baron, J. A. & Prandoni, P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 370, 1773–1779 (2007).
Becattini, C., Vedovati, M. C., Ageno, W., Dentali, F. & Agnelli, G. Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta-analysis. J. Thromb. Haemost. 8, 891–897 (2010).
Bernstein, C. N., Wajda, A. & Blanchard, J. F. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin. Gastroenterol. Hepatol. 6, 41–45 (2008).
Kristensen, S. L. et al. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death—a Danish nationwide cohort study. PLoS ONE 8, e56944 (2013).
Rungoe, C. et al. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut 62, 689–694 (2013).
Avina-Zubieta, J. A., Thomas, J., Sadatsafavi, M., Lehman, A. J. & Lacaille, D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann. Rheum. Dis. 71, 1524–1529 (2012).
Maradit-Kremers, H., Nicola, P. J., Crowson, C. S., Ballman, K. V. & Gabriel, S. E. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 52, 722–732 (2005).
Symmons, D. P. & Gabriel, S. E. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat. Rev. Rheumatol. 7, 399–408 (2011).
Ahlehoff, O. et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J. Intern. Med. 270, 147–157 (2011).
Kristensen, S. L. et al. Inflammatory bowel disease is associated with an increased risk of hospitalization for heart failure: a Danish nationwide cohort study. Circ. Heart Fail. 7, 717–722 (2014).
Yarur, A. J. et al. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am. J. Gastroenterol. 106, 741–747 (2011).
Singh, S., Singh, H., Loftus, E. V. Jr & Pardi, D. S. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 12, 382–393 (2014).
Dorn, S. D. & Sandler, R. S. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am. J. Gastroenterol. 102, 662–667 (2007).
Singh, S. & Loftus, E. V. Jr. Cardiovascular risk in inflammatory bowel disease: it's a heartache! Gastroenterology 145, 1484–1486 (2013).
Ha, C., Magowan, S., Accortt, N. A., Chen, J. & Stone, C. D. Risk of arterial thrombotic events in inflammatory bowel disease. Am. J. Gastroenterol. 104, 1445–1451 (2009).
Shaw, L. J., Bugiardini, R. & Merz, C. N. Women and ischemic heart disease: evolving knowledge. J. Am. Coll. Cardiol. 54, 1561–1575 (2009).
Claassen, M., Sybrandy, K. C., Appelman, Y. E. & Asselbergs, F. W. Gender gap in acute coronary heart disease: myth or reality? World J. Cardiol. 4, 36–47 (2012).
Cook, N. R., Buring, J. E. & Ridker, P. M. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann. Intern. Med. 145, 21–29 (2006).
Andersohn, F., Waring, M. & Garbe, E. Risk of ischemic stroke in patients with Crohn's disease: a population-based nested case-control study. Inflamm. Bowel Dis. 16, 1387–1392 (2010).
Lusis, A. J. Atherosclerosis. Nature 407, 233–241 (2000).
Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685–1695 (2005).
Hansson, G. K., Robertson, A. K. & Soderberg-Naucler, C. Inflammation and atherosclerosis. Annu. Rev. Pathol. 1, 297–329 (2006).
Lorenz, M. W., Markus, H. S., Bots, M. L., Rosvall, M. & Sitzer, M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115, 459–467 (2007).
Papa, A. et al. Increased carotid intima-media thickness in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 22, 839–846 (2005).
Theocharidou, E., Gossios, T. D., Giouleme, O., Athyros, V. G. & Karagiannis, A. Carotid intima-media thickness in patients with inflammatory bowel disease: a systematic review. Angiology 65, 284–293 (2014).
Vlachopoulos, C., Aznaouridis, K. & Stefanadis, C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J. Am. Coll. Cardiol. 55, 1318–1327 (2010).
Zanoli, L. et al. Arterial stiffness is increased in patients with inflammatory bowel disease. J. Hypertens. 30, 1775–1781 (2012).
Zanoli, L. et al. Increased arterial stiffness in inflammatory bowel diseases is dependent upon inflammation and reduced by immunomodulatory drugs. Atherosclerosis 234, 346–351 (2014).
Gutierrez, E. et al. Endothelial dysfunction over the course of coronary artery disease. Eur. Heart J. 34, 3175–3181 (2013).
Anderson, T. J. et al. Microvascular function predicts cardiovascular events in primary prevention: long-term results from the Firefighters and Their Endothelium (FATE) study. Circulation 123, 163–169 (2011).
Pepine, C. J. et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study. J. Am. Coll. Cardiol. 55, 2825–2832 (2010).
Kerekes, G. et al. Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nat. Rev. Rheumatol. 8, 224–234 (2012).
Roifman, I. et al. Evidence of endothelial dysfunction in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 7, 175–182 (2009).
Principi, M. et al. Endothelial function and cardiovascular risk in active inflammatory bowel diseases. J. Crohns Colitis 7, 427–433 (2013).
Aloi, M. et al. Premature subclinical atherosclerosis in pediatric inflammatory bowel disease. J. Pediatr. 161, 589–594 (2012).
Danesh, J. et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350, 1387–1397 (2004).
Averill, M. M., Kerkhoff, C. & Bornfeldt, K. E. S100A8 and S100A9 in cardiovascular biology and disease. Arterioscler. Thromb. Vasc. Biol. 32, 223–229 (2012).
Croce, K. et al. Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation 120, 427–436 (2009).
Ionita, M. G. et al. High myeloid-related protein: 8/14 levels are related to an increased risk of cardiovascular events after carotid endarterectomy. Stroke 41, 2010–2015 (2010).
Jensen, L. J. et al. Plasma calprotectin predicts mortality in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J. Interv. Cardiol. 23, 123–129 (2010).
Oussalah, A., Gueant, J. L. & Peyrin-Biroulet, L. Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases. Aliment. Pharmacol. Ther. 34, 1173–1184 (2011).
Drzewoski, J., Gasiorowska, A., Malecka-Panas, E., Bald, E. & Czupryniak, L. Plasma total homocysteine in the active stage of ulcerative colitis. J. Gastroenterol. Hepatol. 21, 739–743 (2006).
Hankey, G. J. & Eikelboom, J. W. Homocysteine and vascular disease. Lancet 354, 407–413 (1999).
Boushey, C. J., Beresford, S. A., Omenn, G. S. & Motulsky, A. G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274, 1049–1057 (1995).
Koutroubakis, I. E. et al. Anti-cardiolipin and anti-β2-glycoprotein I antibodies in patients with inflammatory bowel disease. Dig. Dis. Sci. 43, 2507–2512 (1998).
Koutroubakis, I. E. et al. Increased levels of lipoprotein (a) in Crohn's disease: a relation to thrombosis? Eur. J. Gastroenterol. Hepatol. 13, 1415–1419 (2001).
Adler, J., Rangwalla, S. C., Dwamena, B. A. & Higgins, P. D. The prognostic power of the NOD2 genotype for complicated Crohn's disease: a meta-analysis. Am. J. Gastroenterol. 106, 699–712 (2011).
Galluzzo, S. et al. Association between NOD2/CARD15 polymorphisms and coronary artery disease: a case-control study. Hum. Immunol. 72, 636–640 (2011).
El Mokhtari, N. E. et al. Role of NOD2/CARD15 in coronary heart disease. BMC Genet. 8, 76 (2007).
Gawaz, M., Langer, H. & May, A. E. Platelets in inflammation and atherogenesis. J. Clin. Invest. 115, 3378–3384 (2005).
Danese, S., Motte Cd Cde, L. & Fiocchi, C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am. J. Gastroenterol. 99, 938–945 (2004).
Webberley, M. J., Hart, M. T. & Melikian, V. Thromboembolism in inflammatory bowel disease: role of platelets. Gut 34, 247–251 (1993).
Collins, C. E., Cahill, M. R., Newland, A. C. & Rampton, D. S. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology 106, 840–845 (1994).
Danese, S. et al. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology 124, 1249–1264 (2003).
Osterman, M. T. et al. No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn's disease. Clin. Gastroenterol. Hepatol. 9, 875–880 (2011).
Inamdar, S., Altafi, S. & Sultan, K. Increased risk of coronary artery disease among patients with inflammatory bowel disease. Gastroenterology 142, S792 (2012).
Haapamaki, J., Roine, R. P., Turunen, U., Farkkila, M. A. & Arkkila, P. E. Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. J. Crohns Colitis 5, 41–47 (2011).
Tan, V. P., Chung, A., Yan, B. P. & Gibson, P. R. Venous and arterial disease in inflammatory bowel disease. J. Gastroenterol. Hepatol. 28, 1095–1113 (2013).
Robertson, J., Peters, M. J., McInnes, I. B. & Sattar, N. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat. Rev. Rheumatol. 9, 513–523 (2013).
Ripolles Piquer, B. et al. Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. Metabolism 55, 980–988 (2006).
Sappati Biyyani, R. S., Putka, B. S. & Mullen, K. D. Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease. J. Clin. Lipidol. 4, 478–482 (2010).
Romanato, G. et al. Plasma lipids and inflammation in active inflammatory bowel diseases. Aliment. Pharmacol. Ther. 29, 298–307 (2009).
Koutroubakis, I. E. et al. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 21, 283–288 (2009).
Wilson, P. W. et al. Prediction of coronary heart disease using risk factor categories. Circulation 97, 1837–1847 (1998).
Sappati Biyyani, R. S., Fahmy, N. M., Baum, E., Nelson, K. M. & King, J. F. Inflammatory bowel disease and coronary artery disease. Indian J. Gastroenterol. 28, 28–30 (2009).
Wei, L., MacDonald, T. M. & Walker, B. R. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann. Intern. Med. 141, 764–770 (2004).
Carty, E., MacEy, M. & Rampton, D. S. Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease. Aliment. Pharmacol. Ther. 14, 1169–1179 (2000).
Prufer, J. et al. Harmful effects of the azathioprine metabolite 6-mercaptopurine in vascular cells: induction of mineralization. PLoS ONE 9, e101709 (2014).
Chung, E. S. et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107, 3133–3140 (2003).
Dixon, W. G. et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 56, 2905–2912 (2007).
Szekanecz, Z., Kerekes, G. & Soltesz, P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat. Rev. Rheumatol. 5, 677–684 (2009).
van Sijl, A. M. et al. Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2013-203934.
Tam, L. S. et al. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis—a randomized trial. J. Rheumatol. 39, 2267–2275 (2012).
Chan, S. S. et al. Aspirin in the aetiology of Crohn's disease and ulcerative colitis: a European prospective cohort study. Aliment. Pharmacol. Ther. 34, 649–655 (2011).
Ananthakrishnan, A. N. et al. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann. Intern. Med. 156, 350–359 (2012).
Takeuchi, K. et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 4, 196–202 (2006).
Vinod, J. et al. The effect of antiplatelet therapy in patients with inflammatory bowel disease. J. Clin. Gastroenterol. 46, 527–529 (2012).
Patel, S. H., Rachchh, M. A. & Jadav, P. D. Evaluation of anti-inflammatory effect of anti-platelet agent-clopidogrel in experimentally induced inflammatory bowel disease. Indian J. Pharmacol. 44, 744–748 (2012).
Carty, E., Rampton, D. S., Schneider, H., Rutgeerts, P. & Wright, J. P. Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease. Aliment. Pharmacol. Ther. 15, 1323–1329 (2001).
Tytgat, G. N., Van Nueten, L., Van De Velde, I., Joslyn, A. & Hanauer, S. B. Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies. Aliment. Pharmacol. Ther. 16, 87–99 (2002).
Ky, B. & Rader, D. J. The effects of statin therapy on plasma markers of inflammation in patients without vascular disease. Clinical Cardiol. 28, 67–70 (2005).
Lee, J. Y. et al. Simvastatin inhibits NF-κB signaling in intestinal epithelial cells and ameliorates acute murine colitis. Int. Immunopharmacol. 7, 241–248 (2007).
Naito, Y. et al. Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice. Int. J. Mol. Med. 17, 997–1004 (2006).
Sasaki, M. et al. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis. J. Pharmacol. Exp. Ther. 305, 78–85 (2003).
Abe, Y. et al. Simvastatin attenuates intestinal fibrosis independent of the anti-inflammatory effect by promoting fibroblast/myofibroblast apoptosis in the regeneration/healing process from TNBS-induced colitis. Dig. Dis. Sci. 57, 335–344 (2012).
Grip, O. & Janciauskiene, S. Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease. PLoS ONE 4, e5263 (2009).
Crockett, S. D. et al. Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study. Inflamm. Bowel Dis. 18, 1048–1056 (2012).
Cho, S. J. et al. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int. J. Cancer 123, 951–957 (2008).
Samadder, N. J. et al. Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use. Cancer 117, 1640–1648 (2011).
Jaszewski, R. et al. Increased colonic mucosal angiotensin I and II concentrations in Crohn's colitis. Gastroenterology 98, 1543–1548 (1990).
Wengrower, D. et al. Prevention of fibrosis in experimental colitis by captopril: the role of TGF-β1. Inflamm. Bowel Dis. 10, 536–545 (2004).
Crowson, C. S. et al. Rheumatoid arthritis and cardiovascular disease. Am. Heart J. 166, 622–628 (2013).
Aggarwal, A., Atreja, A., Kapadia, S., Lopez, R. & Achkar, J. P. Conventional risk factors and cardiovascular outcomes of patients with inflammatory bowel disease with confirmed coronary artery disease. Inflamm. Bowel Dis. 20, 1593–1601 (2014).
Author information
Authors and Affiliations
Contributions
S.S. and E.V.L. contributed to researching data for the article, discussion of content, writing the article and reviewing/editing the manuscript before submission. I.J.K. contributed to discussion of the content and reviewing/editing the manuscript before submission. D.S.P. contributed to discussion of content, writing the article and reviewing/editing the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Table 1
Summary of key clinical studies on incidence and risk of stroke and myocardial infarction in patients with IBD (PDF 29 kb)
PowerPoint slides
Rights and permissions
About this article
Cite this article
Singh, S., Kullo, I., Pardi, D. et al. Epidemiology, risk factors and management of cardiovascular diseases in IBD. Nat Rev Gastroenterol Hepatol 12, 26–35 (2015). https://doi.org/10.1038/nrgastro.2014.202
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2014.202
This article is cited by
-
Investigation of the anti-inflammatory effects of native potential probiotics as supplementary therapeutic agents in an in-vitro model of inflammation
BMC Complementary Medicine and Therapies (2023)
-
Prevalence of cerebrovascular accidents in patients with ulcerative colitis in a single academic health system
Scientific Reports (2022)
-
Impact of inflammatory bowel disease on hospital outcomes in acute ischemic stroke: a nationwide cohort study
International Journal of Colorectal Disease (2021)
-
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease
Nature Reviews Gastroenterology & Hepatology (2021)
-
Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease
BMC Medicine (2017)